Aktienanalyse zu AtriCure, Inc. (ATRC)ATRCAtriCure, Inc.

AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

AtriCure Inc is currently a hold. The stock is priced at $56.07, which is close to the median analyst price target of $57, suggesting limited upside. Additionally, the RSI is at 48.016, indicating a neutral momentum, and the forward P/E ratio is very high at 232.56, which may indicate overvaluation. The main risk is the recent insider selling, where the CTO sold shares worth approximately $201,000, which could signal caution among insiders.

8 analysts cover ATRC: 7 rate it Buy, 1 Hold and 0 Sell. The average price target is 52.20.